title: Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: Edward
authors.initials: E
authors.lastname: Keystone
authors.forename: JingYuan
authors.initials: J
authors.lastname: Feng
authors.forename: Michele
authors.initials: M
authors.lastname: Hooper
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate